EXEMPTIA 20MG INJECTION

Same day

Introduction:

Benzace 40mg Tablet contains the active substance Megestrol. It belongs to a category of medications called progestogens and is used to treat certain hormone-dependent cancers, such as breast cancer. It is a synthetic form of the naturally occurring progesterone hormone. It is also indicated to treat unexplained weight loss, weakness and loss of appetite in patients with weak immune system and cancer.

 

Progestogen therapy is useful for patients whose disease has progressed with conventional anti-estrogen therapy. Your physician will assess the estrogen status (ER) to ensure that your breast cancer is due to the expression of the estrogen receptor.

 

Uses of Benzace 40mg Tablet:

Benzace 40mg Tablet is used to treat the following conditions:

  • Hormone-dependent cancer (endometrial cancer, breast cancer)
  • Unexplained weight loss, weakness and loss of appetite in patients with weak immune system and cancer.

 

How Benzace 40mg Tablet works:

Benzace 40mg Tablet exhibits anticancer properties by interacting with steroidal receptors. It suppresses steroid production by the adrenal glands and androgen secretion by the ovaries in postmenopausal women. It also prevents the breakdown of cytokines and stimulates appetite in chronic disease-induced anorexia and cachexia.

 

Interaction with other drugs:

Inform your doctor about any medications you are taking or have taken before the treatment.

 

More Information:

Store at a temperature below 25°C, protected from light and moisture. Keep medicine out of reach of children.

 

References:

  1. Bausch and Lomb UK Ltd., Electronic Medicines Compendium (EMC), [Revised on Sep 2020] [Accessed on 17th Jul 2021], https://www.medicines.org.uk/emc/files/pil.11135.pdf
  2. alniche Life Sciences Pvt Ltd., [Revised on 2021] [Accessed on 19th Jul 2021], https://www.alniche.com/product/megahenz/
  3. Bines et al., Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial, Annals of Oncology, 2014, 25(4), 831-836, https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2819%2936501-9
  4. G.G. Dark, A.R. Abdul Razak, Oncology, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 259-282.

Disclaimer: City Medicine Corner primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on City Medicine Corner. Our mission is to support, not replace, the doctor-patient relationship.

Enquiry Now